The increase in price target by Piper Sandler suggests a bullish outlook on Biohaven, which could lead to increased investor confidence and a potential rise in the stock price in the short term. As the rating is maintained at Overweight, it reflects a continued positive sentiment from the analyst, which is likely to be taken seriously by the market.